Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Business Wire•22/10/2026•06:00 ET
0
Key Highlights
- ➤10 ESMO 2026 presentations will feature ivonescimab across multiple tumor types
- ➤HARMONi-GI1 Phase III showed positive overall survival in first-line advanced biliary tract cancer
- ➤EA2251 Phase II/III study will test ivonescimab combinations in U.S. biliary tract cancer
- ➤Endometrial cancer Phase II met its objective response rate primary endpoint
- ➤ESMO program includes Phase II data in renal cell and thymic carcinomas
Expert Statements
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“The breadth of the ivonescimab data at ESMO underscores the expanding body of clinical evidence across a diverse range of tumor types and treatment settings”
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“Our ambition for ivonescimab extends beyond any single indication.”
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“We are focused on advancing a rigorous clinical development program to determine where this novel IO bispecific antibody could make a meaningful difference for patients.”
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“We look forward to engaging with the global oncology community on these data at ESMO 2026.”
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Highlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab
Get started
Create a free account to read the full story.